Scientific Poster Session IV - Students Research-in-Progress

Abstract

Intravenous Lipid Emulsion Impact on Length of Hospital Stay for Pediatric Patients with Overdose Toxicity

Introduction: Since not all drugs have a specific antidote, it is necessary to explore other options for detoxification therapy in drug overdose cases. Intravenous lipid emulsions (ILE) have chelating and drug sequestrating properties that can aid in the detoxification process and improve outcomes. Studies are needed to determine if ILE is an effective therapy for drug overdose and will be studied specifically in the pediatric population.

Research Question or Hypothesis: Does intravenous lipid emulsion administration in patients with an overdose toxicity reduce the length of hospital stay? Which toxicities are most impacted by liposome administration?

Study Design: Retrospective cohort study using data from Cook Children’s Medical Center comparing length of hospital stay in patients who were treated with liposomes to patients who did not receive liposomes after presenting to the emergency department with an overdose toxicity.

Methods: Pediatric patients (<18 years) who presented to the emergency department with an overdose toxicity between 2020 and 2023 without co-morbidities are included. The primary outcome for the study will be the length of hospital admission, and a t-test will be used to report the average length of stay between the group who received liposomes and the group who did not. Average length of stay will also be compared between various types of toxicities to determine if liposome therapy was more impactful in decreased length of admission in a specific toxicity.

Results: The results are still in-progress, but are trending toward a decreased average stay by 2 days for patients who received liposomes as therapy for toxicity. Results will be finalized and fully analyzed by September 2024.

Conclusion: To be determined.

Presenting Author

Authors